https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13671 Wed 11 Apr 2018 16:06:02 AEST ]]> Comparative efficacy of switching to natalizumab in active multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> A comparative analysis of patient-reported expanded disability status scale tools https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26131 Wed 11 Apr 2018 14:53:18 AEST ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Multiple Sclerosis Relapses Following Cessation of Fingolimod https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12845 T at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10−8) near EOMES, rs2150702G in the second intron of MLANA on chromosome 9p24.1 (OR, 1.16; p = 3.3 × 10−8), and rs6718520A in an intergenic region on chromosome 2p21, with THADA as the nearest flanking gene (OR, 1.17; p = 3.4 × 10−8). The 3 new loci do not have a strong cis effect on RNA expression in PBMCs. Ten other susceptibility loci had a suggestive p < 1 × 10−6, some of these loci have evidence of association in other inflammatory diseases (ie, IL12B, TAGAP, PLEK, and ZMIZ1). Interpretation: We have performed a meta-analysis of GWAS in MS that more than doubles the size of previous gene discovery efforts and highlights 3 novel MS susceptibility loci. These and additional loci with suggestive evidence of association are excellent candidates for further investigations to refine and validate their role in the genetic architecture of MS.]]> Sat 24 Mar 2018 08:17:22 AEDT ]]> Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]>